Intrahepatic arterial infusion of chemotherapy: clinical results.

Semin Oncol

Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Published: April 2002

Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial infusion (HAI) of chemotherapy. Randomized data in this field have been hampered due to small numbers of patients in some trials, or crossover between groups. However, most trials have suggested an improvement in both overall and progression-free survival with HAI therapy. Dose-limiting toxicity associated with HAI is related to hepatobiliary sclerosis, which has been reduced with the use of dexamethasone as part of the treatment. Current research is underway to improve the rate of extrahepatic metastases in patients undergoing HAI.

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2002.31680DOI Listing

Publication Analysis

Top Keywords

arterial infusion
8
intrahepatic arterial
4
infusion chemotherapy
4
chemotherapy clinical
4
clinical 60%
4
60% patients
4
patients diagnosed
4
diagnosed colorectal
4
colorectal cancer
4
cancer crc
4

Similar Publications

Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers.

Methods: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing.

View Article and Find Full Text PDF

Background: Infiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced HCC, but its role in advanced infiltrative HCC is unclear. This study aims to investigate the efficacy and safety of HAIC combined with ICIs and MTTs in the treatment of advanced infiltrative HCC.

View Article and Find Full Text PDF

Vascular research of pig knee from the perspective of comparative medicine.

Ann Vasc Surg

January 2025

Department of Orthopedics, SiJing Hospital of SongJiang District, Shanghai, China. Electronic address:

Objective: Pigs have long been employed as an animal model for knee-related diseases. However, vascular anatomy around the pig knee is rare. The objective of this study was to explore the vascular anatomy around the pig knee from the perspective of comparative medicine.

View Article and Find Full Text PDF

This study investigated the correlation between quantitative echocardiographic characteristics within 3 days of birth and necrotizing enterocolitis (NEC) and its severity in preterm infants. A retrospective study was conducted on 168 preterm infants with a gestational age of < 34 weeks. Patients were categorized into NEC and non-NEC groups.

View Article and Find Full Text PDF

Objective: To determine the effects of rapid (1 minute) and slow (10 minutes) intravenous (IV) injection of sodium penicillin on arterial blood pressure in anesthetized horses.

Study Design: Prospective randomized clinical trial.

Animals: A group of 29 client-owned horses of various breeds, 1-20 years old, with body masses of 360-710 kg.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!